Biotechnology & Medical Research

Neurocrine Biosciences Inc receives breakthrough therapy designation for NBI-98854 in Tardive Dyskinesia

Neurocrine Biosciences Inc:Says U.S. FDA has granted breakthrough therapy designation for its vesicular monoamine transporter 2 inhibitor, NBI-98854, in tardive dyskinesia.Breakthrough therapy designation is granted for drug that is intended to treat serious or life-threatening disease or condition...

7:30am EDT

Acorda Therapeutics Inc raises FY 2014 AMPYRA net revenue outlook

Acorda Therapeutics Inc:Raised FY 2014 guidance for AMPYRA Net Revenue from $328-$335 mln to $345-$350 mln.

6:02am EDT

Quintiles Transnational Holdings Inc raises FY 2014 EPS guidance

Quintiles Transnational Holdings Inc:Raised diluted adjusted EPS to a range $2.61-$2.68 per share and diluted GAAP EPS between $2.61-$2.68 per share.FY 2014 EPS of $2.64 - Thomson Reuters I/B/E/S.

6:00am EDT

Chiome Bioscience Inc amends consolidated full-year outlook for FY 2014

Chiome Bioscience Inc:Says the company amended the consolidated full-year outlook for the FY ending Dec. 2014.Revenue forecast decreased to 277 million yen from 342 million yen.Operating profit forecast increased to a loss of 907 million yen from a loss of 1,043 million yen.Ordinary profit forecast...

3:00am EDT

Expansion & New Markets

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: Thomson Reuters StreetEvents
$75.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.